Neumann Mark 4

What Happened Mark Neumann, Chief Commercial Officer and Strategy Officer of Veradermics (MANE), was granted a derivative award of 102,885 shares (reported as an option grant) on February 3, 2026. The Form 4 records the acquisition under transaction code "A" (award/grant) and lists a price of $0.00 for the transaction. This is an equity compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-03 (Form 4 filed 2026-02-05; appears timely).
• Award: 102,885 derivative shares (option grant), transaction code A.
• Price reported in filing: $0.00 (listed on Form 4).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting (footnote): 25% of the underlying shares vest on Feb 3, 2027 (one-year cliff); remaining shares vest in equal monthly installments over the following 36 months, subject to continued service.
• Not an exercise or immediate sale—this is a grant of an equity award.

Context This filing reflects a standard executive equity grant used for compensation and retention. As a derivative option award, the grant vests over time per the schedule above; it does not represent an immediate open-market purchase or sale of shares. No additional indicators (such as a cashless exercise or sale) are shown in this filing.